죽상 동맥경화증과 연관된 허혈성 뇌졸중 환자에서 클로피도그렐의 혈소판 응집억제효과 및 내성에 대한 연구

Abstract

Background : The efficacy and safety of clopidogrel in preventing ischemic events have been proven in a randomized double blinded trial(clopidogrel versus aspirin in patients at risk of ischemic events study; CAPRIE). There, also, were many studies confirming in vitro anti-aggregating activity of clopidogrel. Our objective is to determine the pharmacological activity and tolerance of clopidogrel in the patients with ischemic stroke. Patients and Methods : 66 patients who experienced atherosclerotic ischemic stroke participated in the study. They were given clopidogrel at a dose of 75㎎daily for 21days. ADP induced platelet aggregation and bleeding time were tested before starting treatment, 7 and 21 days after treatment. Results : In the presence of ADP(5μM) this inhibition ranged between 43.6% and 55.5% in comparison with pretreatment values. This effect was not significantly different from the previous studies. The clinical tolerance was good or fair in 94% of the patients. No serious adverse events were recorded. Conclusion : Clopidogrel exerted inhibition of ADP induced platelet aggregation and bleeding time prolongation. Our results showed clinical efficacy, pharmacological activity and tolerance of clopidogrel in Korean population. Korean Journal of Stroke 1999;1(1):47~51